All News

The podcast highlights addressing misinformation, the impact of celebrity endorsements in pharmaceuticals, and the important role of pharmacists in educating patients.

Many psychedelics being studied for clinical use are not "magic mushrooms", rather clinical drugs formulated using good manufacturing practice standards.

For more than 30 years, there has been little treatment advancement for NMIBC patients. Fortunately, a new development in the treatment of NMIBC has been approved by the FDA and is now available.

After 48 weeks of treatment with survodutide, patients demonstrated histological improvement, a reduction in liver fat content, and did not experience worsening fibrosis.

The ACCC 50th Annual Meeting & Cancer Center Business Summit is taking place in Washington, DC from February 28 to March 1.

Gepotidacin was compared with the combination of ceftriaxone and azithromycin in adolescent and adult patients with uncomplicated urogenital gonorrhea.

The data follow the FDA approval of omalizumab for the reduction of allergic reactions, including anaphylaxis, that can occur after exposure to 1 or more foods.

The results were presented as a late-breaking poster presentation at the American Academy of Allergy, Asthma, and Immunology Annual Meeting.

Tune into this episode of "Public Health Matters" to learn about the importance of cultural competence when addressing health care disparities and promoting health equity in diverse communities as well as special guest Dr. Jose Cucalon Calderon's advocacy work.

The new indication includes individuals with HIV who have suppressed viral loads with known or suspected M184V/I resistance.

In addition to current treatment regimens, 2 experts discuss how available options can vary between adult and pediatric patients.

Experts sheds light on gaps in gender and use of referrals, health literacy, and medication access in the treatment of patients with heart failure.

Investigators found genetic evidence that certain sleep behaviors can be risk factors for lifespan.

“I’m better than I was before I had long COVID, and in so many ways,” said a patient in an interview with Pharmacy Times.

The sNDA was based on results from the KRYSTAL-1 study, evaluating the drug alone or in combination with other anti-cancer therapies in those with advanced solid tumors who have KRASG12C mutations.

The withdrawal comes after clinical trial results failed to demonstrate the safety and efficacy of melphalan flufenamide when combined with dexamethasone.

Adalimumab-ryvk is the first high-concentration, citrate-free biosimilar to Humira that has been granted interchangeability status for the 40 mg/0.4 ml injection.

The recommendation comes after positive phase 3 trial results in adult patients with relapsed and refractory multiple myeloma.

A brief overview of 4 recent developments in the treatment of non-small cell lung cancer.

Investigators continue to conduct regulated and controlled clinical trials to build compelling, high-quality evidence on their therapeutic potential.

As of January 2024, Keytruda has been approved for 6 indications in NSCLC across the metastatic and earlier stages of the disease.

Pharmacists could raise awareness of heart health and CPR through community outreach programs

In addition to highlighting the difficulties patients face when managing plaque psoriasis and atopic dermatitis, 2 experts describe how pharmacists play a crucial role in treatment.

Four years after congress passed it, the Hannon Act is helping veterans get better care

The question arose whether the court would allow the pharmacist to recover his attorney fees

The evolution of pharmacy, as a practice and profession, is unique in that its evolution has quickened exponentially in just the past 20 years.

The model implemented at City of Hope Chicago has been shown to improve provider workloads and enrich pharmacists’ work.

Dedicated clinical trials in IBD cohorts that scrutinized biosimilar use in real-world clinical practice have direct implications on decision making.

Investing in community relationships and health literacy are key steps pharmacists can take to improve equity.

Data shed light on brentuximab vedotin plus nivolumab, bendamustine, or gemcitabine.